Animal Models of Ischemia
There is no generally accepted specific therapy for most types of focal strokes. A major problem in rational development of therapies has been the difficulty determining whether a proposed therapy is effective. Appropriate studies in patients are complex, and few animal models are adequate for realistic and efficient tests of pharmacologic methods to reduce damage or restore neurologic function. Most cerebral stroke models have not been designed to detect whether therapy reduces neurologic injury but are intended to mimic the clinical and pathologic features of human strokes. For pharmacologic trials, a method of producing incremental grades of destruction is desirable and this is difficult to achieve with most focal stroke models. Also, regardless of the species, the infarcts vary unpredictably in size and distribution (Molinari and Laurent, 1976; Yatsu, 1976; Waltz, 1979). This degree of variability makes therapeutic trials expensive because many subjects are required. Similarly, biochemical analysis is hampered by the inability to predict the precise locations of lesions, and the marked biochemical heterogeneity of the brain complicates interpretation of the results. Since no single technique is optimal for all types of investigations, we have developed a series of stroke models that we use in a coordinated fashion for biochemical and pharmacologic studies of focal ischemia.
KeywordsSpinal Cord Neurologic Function Focal Cerebral Ischemia Cresyl Violet Stroke Model
Unable to display preview. Download preview PDF.
- Kety SS (1951): Theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol Rev 3: 4–41Google Scholar
- Yatsu FM (1976): Biochemical mechanisms of ischemic brain infarction. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW, eds. New York: American ElsevierGoogle Scholar